全文获取类型
收费全文 | 943613篇 |
免费 | 68951篇 |
国内免费 | 5885篇 |
专业分类
耳鼻咽喉 | 12960篇 |
儿科学 | 29016篇 |
妇产科学 | 26604篇 |
基础医学 | 130711篇 |
口腔科学 | 25428篇 |
临床医学 | 80668篇 |
内科学 | 188174篇 |
皮肤病学 | 19339篇 |
神经病学 | 73288篇 |
特种医学 | 38438篇 |
外国民族医学 | 358篇 |
外科学 | 147305篇 |
综合类 | 29403篇 |
现状与发展 | 6篇 |
一般理论 | 253篇 |
预防医学 | 67865篇 |
眼科学 | 21507篇 |
药学 | 69233篇 |
59篇 | |
中国医学 | 5314篇 |
肿瘤学 | 52520篇 |
出版年
2021年 | 8000篇 |
2019年 | 8184篇 |
2018年 | 10982篇 |
2017年 | 8931篇 |
2016年 | 9422篇 |
2015年 | 11352篇 |
2014年 | 15621篇 |
2013年 | 22321篇 |
2012年 | 30369篇 |
2011年 | 32085篇 |
2010年 | 19997篇 |
2009年 | 18505篇 |
2008年 | 29106篇 |
2007年 | 30626篇 |
2006年 | 30566篇 |
2005年 | 29844篇 |
2004年 | 27819篇 |
2003年 | 26780篇 |
2002年 | 26062篇 |
2001年 | 42111篇 |
2000年 | 43132篇 |
1999年 | 36749篇 |
1998年 | 9768篇 |
1997年 | 8903篇 |
1996年 | 8777篇 |
1995年 | 8686篇 |
1994年 | 8301篇 |
1993年 | 7699篇 |
1992年 | 28309篇 |
1991年 | 27112篇 |
1990年 | 26528篇 |
1989年 | 25433篇 |
1988年 | 23635篇 |
1987年 | 23235篇 |
1986年 | 22309篇 |
1985年 | 21201篇 |
1984年 | 15822篇 |
1983年 | 13472篇 |
1982年 | 8062篇 |
1979年 | 14580篇 |
1978年 | 10191篇 |
1977年 | 8604篇 |
1976年 | 8124篇 |
1975年 | 8945篇 |
1974年 | 10686篇 |
1973年 | 10174篇 |
1972年 | 9665篇 |
1971年 | 8911篇 |
1970年 | 8579篇 |
1969年 | 8021篇 |
排序方式: 共有10000条查询结果,搜索用时 171 毫秒
81.
82.
L. Piram T. Frédéric-Moreau R. Bellini F. Martin J. Miroir N. Saroul N. Pham Dang J. Biau M. Lapeyre 《Cancer radiothérapie》2019,23(3):272-269
Salivary glands tumours are uncommon tumours showing a large diversity of histological types. This article presents a synthesis of patterns and paths of invasion of parotid glands tumours in order to propose an approach of the delineation of primary tumour clinical target volumes and of the selection of lymph nodes target volumes. This article does not discuss treatment indications but defines clinical target volumes to treat if radiotherapy is indicated. Postoperative situation being the most frequent, the delineation of primary tumour clinical target volume is based on an anatomical approach. 相似文献
83.
Ellen Strijbos Martijn R. Tannemaat Iris Alleman Robert H.P. de Meel Jaap A. Bakker Ruud van Beek Frank P. Kroon Guus F. Rimmelzwaan Jan J.G.M. Verschuuren 《Vaccine》2019,37(7):919-925
Objective
To investigate the efficacy and safety of an influenza vaccination in patients with myasthenia gravis with acetylcholine receptor antibodies (AChR MG).Methods
An influenza vaccination or placebo was administered to 47 AChR MG patients. Before and 4?weeks after administration blood samples and clinical outcome scores were obtained. Antibodies to the vaccine strains A/California/7/2009 (H1N1)pdm09, A/Hong Kong/4801/14 (H3N2) and B/Brisbane/060/08 were measured using the hemagglutination-inhibition (HI) assay and disease-specific AChR antibody titers were measured with a radio-immunoprecipitation assay. Forty-seven healthy controls (HC) were vaccinated with the same influenza vaccine to compare antibody titers.Results
A post-vaccination, seroprotective titer (HI?≥?1:40) was achieved in 89.4% of MG patients vs. 93.6% in healthy controls for the H3N2 strain, 95.7% vs 97.9% for the H1N1 strain and 46.8 vs 51% for the B-strain. A seroprotective titer for all three strains of the seasonal influenza vaccine was reached in 40.4% (19/47) of the MG group and in 51% (24/47) of the HC group. Immunosuppressive medication did not significantly influence post geomean titers (GMT). The titers of disease-specific AChR antibodies were unchanged 4?weeks after vaccination. The clinical outcome scores showed no exacerbation of MG symptoms.Conclusion
The antibody response to an influenza vaccination in patients with AChR MG was not different from that in healthy subjects, even in AChR MG patients using immunosuppressive medication. Influenza vaccination does not induce an immunological or clinical exacerbation of AChR MG.Clinical trial registry
The influenza trial is listed on clinicaltrialsregister.eu under 2016-003138-26. 相似文献84.
Baoan Hong Lin Cai Jiangyi Wang Shengjie Liu Jingcheng Zhou Kaifang Ma Jiufeng Zhang Bowen Zhou Xiang Peng Ning Zhang Kan Gong 《Clinical genitourinary cancer》2019,17(2):97-104.e1
Background
Programmed death ligand-1 (PD-L1) is a potential predictive biomarker for immunotherapy in several malignancies. However, the expression level and clinical significance of PD-L1 in von Hippel–Lindau (VHL)-associated hereditary clear-cell renal cell carcinoma (ccRCC) remain unclear.Patients and Methods
Surgical specimens were recruited from 129 patients with sporadic ccRCC and 26 patients with VHL-associated hereditary ccRCC. The PD-L1 expression level was assessed using immunohistochemistry. Correlations between PD-L1 expression and clinicopathological features were analyzed.Results
In sporadic ccRCC, the positive expression rate of PD-L1 was 47.3% (61/129). Positive PD-L1 expression was correlated with advanced tumor T stage (P = .011), higher Fuhrman nuclear grade (P = .022), poor disease-free survival (P = .037), and sex (P = .025). In the VHL-associated hereditary ccRCC, positive PD-L1 expression rate was 34.6% (9/26), lower than that in sporadic ccRCC. Positive PD-L1 was correlated with higher Fuhrman nuclear grade (P = .008), but not with sex, age, tumor stage, or the onset age of VHL-associated tumors.Conclusion
Positive PD-L1 expression was correlated with the aggressive clinicopathological features in sporadic and VHL-associated hereditary ccRCC. Whether PD-L1 expression level in ccRCC is related to the effectiveness of programmed death-1/PD-L1 checkpoint inhibitor immunotherapy needs to be further investigated. 相似文献85.
86.
87.
Samir Gupta MD MSCS Gloria D. Coronado PhD Keith Argenbright MD Alison T. Brenner PhD MPH Sheila F. Castañeda PhD Jason A. Dominitz MD MHS Beverly Green MD MPH Rachel B. Issaka MD MAS Theodore R. Levin MD Daniel S. Reuland MD MPH Lisa C. Richardson MD MPH Douglas J. Robertson MD MPH Amit G. Singal MD MS Michael Pignone MD MPH 《CA: a cancer journal for clinicians》2020,70(4):283-298
Uptake of colorectal cancer screening remains suboptimal. Mailed fecal immunochemical testing (FIT) offers promise for increasing screening rates, but optimal strategies for implementation have not been well synthesized. In June 2019, the Centers for Disease Control and Prevention convened a meeting of subject matter experts and stakeholders to answer key questions regarding mailed FIT implementation in the United States. Points of agreement included: 1) primers, such as texts, telephone calls, and printed mailings before mailed FIT, appear to contribute to effectiveness; 2) invitation letters should be brief and easy to read, and the signatory should be tailored based on setting; 3) instructions for FIT completion should be simple and address challenges that may lead to failed laboratory processing, such as notation of collection date; 4) reminders delivered to initial noncompleters should be used to increase the FIT return rate; 5) data infrastructure should identify eligible patients and track each step in the outreach process, from primer delivery through abnormal FIT follow-up; 6) protocols and procedures such as navigation should be in place to promote colonoscopy after abnormal FIT; 7) a high-quality, 1-sample FIT should be used; 8) sustainability requires a program champion and organizational support for the work, including sufficient funding and external policies (such as quality reporting requirements) to drive commitment to program investment; and 9) the cost effectiveness of mailed FIT has been established. Participants concluded that mailed FIT is an effective and efficient strategy with great potential for increasing colorectal cancer screening in diverse health care settings if more widely implemented. 相似文献
88.
89.
目的比较正常剂量盐酸氨溴索联合排痰仪与大剂量盐酸氨溴索联合支气管镜在治疗老年重症肺炎中的临床疗效。方法通过计算机检索PubMed、The Cochrane Library、Web of Science、CNKI、万方数据库、维普数据库和中国生物医学文献服务系统,搜索国内外公开发表的有关盐酸氨溴索联合排痰仪与大剂量盐酸氨溴索联合支气管镜治疗老年重症肺炎的相关文章,检索时限从建库起到2019年5月。分别由两名作者根据文献纳入和排除标准对文献进行筛选以及数据提取,使用RevMan 5.3软件进行Meta分析。结果经筛选后共有27篇文献最终被纳入分析。Meta分析结果表明,大剂量盐酸氨溴索联合支气管镜治疗能减少患者ICU住院时间(MD=-1.84,95%CI:-2.21~-1.48)、呼吸机使用时间(MD=-3.93,95%CI:-4.17~-3.69)、治疗期间死亡率(O^R=0.42,95%CI:0.33~0.53)、急性生理学与慢性健康状况(APACHEⅡ)评分(MD=-0.67,95%CI:-1.05~-0.29)、多器官功能衰竭(MOF)发生率(O^R=0.41,95%CI:0.32~0.53)、C反应蛋白(CRP)浓度(MD=-10.35,95%CI:-11.29~-9.41)以及血清降钙素原(PCT)浓度(MD=-0.37,95%CI:-0.40~-0.33),增加患者动脉血氧分压(PaO_2)(MD=4.85,95%CI:3.83~5.86)、经皮动脉血氧饱和度(SpO_2)(MD=6.47,95%CI:5.65~7.29)和氧合指数(OI)(PaO_2/FiO_2)(MD=31.88,95%CI:29.21~34.54)。结论大剂量使用盐酸氨溴索联合支气管镜治疗老年重症肺炎是安全可行的,且与常规治疗方法相比,在所测指标中均具有一定的优势,有望成为治疗老年重症肺炎的优先选择。 相似文献
90.
Allison F. O’Neill MD Caihong Xia PhD Mark D. Krailo PhD Furqan Shaikh MD MSc Farzana D. Pashankar MD MRCP Deborah F. Billmire MD Thomas A. Olson MD Jim F. Amatruda MD PhD Doojduen Villaluna MS Li Huang MS Marcio Malogolowkin MD Carlos Rodriguez-Galindo MD A. Lindsay Frazier MD 《Cancer》2019,125(20):3649-3656